Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vildagliptin and glucose variability in type 2 diabetes
2011-006049-14Phase 4Terminated
- Sponsor
- University of Birmingham
- Start
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of vildagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by University of Birmingham. Primary endpoint: Glycaemic variability, hypoglycaemia, oxidative stress, and cardiac risk profile comparison. Started Feb 2012; status: terminated.
02
Drugs
vildagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2011-006049-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-006049-14.